We report the results of two prospective phase II studies investigating the role of high-dose sequential chemotherapy, followed by autologous stem cell transplantation (ASCT) in 62 patients with advanced stage peripheral T-cell lymphomas (PTCLs) at diagnosis. Conditioning regimen consisted of mitoxantrone (60 mg/m 2 ) and melphalan (180 mg/m 2 ) or carmustine, etoposide, Ara-C and melphalan followed by peripheral blood stem cell autografting. In an intent-to-treat analysis, 46 out of 62 patients (74%) completed the whole programme, whereas 16 patients did not undergo ASCT, mainly because of disease progression. At a median follow-up of 76 months, the estimated 12-year overall (OS), disease-free and event-free survival (EFS) were 34, 55 and 30%, respectively. OS and EFS were significantly better in patients with anaplastic lymphomakinase (ALK)-positive anaplastic large-cell lymphoma (ALCL), as compared with the remaining PTCL. Multivariate analysis showed that patients attaining complete remission (CR) before ASCT had a statistically significant benefit in terms of OS and EFS (Po0.0001). Overall treatment-related mortality rate was 4.8%. In conclusion, our findings indicate (1) up-front high-dose therapy and ASCT are feasible, but could induce a high rate of long-term CR only in patients with ALK-positive ALCL and (2) the achievement of CR before autografting is a strong predictor of better survival.
Introduction
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of malignancies characterized by an aggressive behaviour and a poor outcome after conventional chemotherapy. A French prospective study reported a 5-year overall survival (OS) rate of 41% and an event-free survival (EFS) rate of 33% with anthracycline-containing chemotherapy regimens. 1 In order to improve the prognosis of PTCL, alternative strategies including high-dose therapy and autografting have been considered. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is considered an effective treatment for patients with relapsed diffuse large B-cell lymphoma or for those presenting with a high International Prognostic Index score at diagnosis. 2, 3 However, the role of ASCT in PTCL is still unclear. The rarity of T-cell lymphoma and the histologic heterogeneity of subtypes identified as PTCL have caused for many years a great difficulty to perform large prospective trials.
Some retrospective studies using intensive chemotherapy and ASCT in relapsed/refractory patients with T-cell lymphoma showed that this approach was an effective salvage treatment, resulting in approximately 25-35% EFS. 4, 5 However, results were definitively more satisfactory in anaplastic lymphomakinase (ALK)-positive anaplastic large-cell lymphomas (ALCLs) compared to the other PTCL subtypes. 6, 7 In addition, the risk of disease relapse or progression after autografting remained high. Very few data are available on the up-front use of ASCT in PTCL. 8, 9 The impact of ASCT on the outcome of distinct PTCL subtypes, defined according to the Revised European-American Lymphoma (REAL) classification, has not been determined yet.
In the present study, we report the results of a long-term analysis performed on a large series of PTCL patients treated at diagnosis with high-dose chemotherapy followed by peripheral blood progenitor cell (PBPC) autografting.
Materials and methods

Patients' characteristics
Between January 1993 and December 2003, 62 patients with stage II-IV PTCL at diagnosis and age less than 60 years were enrolled in two prospective phase II studies: one was performed at the University of Turin (Turin, Italy) and the Istituto Nazionale Tumori (Milan, Italy), and the other at the Ospedale Riuniti (Bergamo, Italy).
Patients gave written informed consent to participate in the study protocol, which was approved by local ethical committee. The eligibility criteria were as follows: (i) age between 18 and 60 years; (ii) negative serologic markers for human immunodeficiency virus, hepatitis B virus and hepatitis C virus; (iii) no major organ dysfunction for causes unrelated to lymphoma and (iv) histologically proven diagnosis of PTCL, according to the Kiel classification (before 1994) or according to the REAL classification (after 1994). Patients with lymphoblastic lymphoma and mycosis fungoides/Sezary syndrome or cutaneous lymphomas were excluded from the study. Histologic PTCL subtypes included PTCL unspecified (n ¼ 28), ALK-positive ALCL (n ¼ 19), angioimmunoblastic lymphomas (n ¼ 10) and other subtypes (n ¼ 5, four ALK-negative ALCL and one enteropathyassociated ALCL). Patients had a median age of 43 years (range, 20-60 years). Fifty-one patients (82%) had an advanced stage disease at diagnosis (stage III/IV), whereas the remaining were stage II, and 71% presented with two or more adverse risk factors according to the age-adjusted International Prognostic Index (aaIPI). Main patient characteristics according to treatment plan are illustrated in Table 1 .
Treatment plan
Thirty-two patients received an intensified version of the highdose sequential chemotherapy regimen, 10 which consisted of (i) debulking phase with two APO courses (doxorubicin 75 mg/m 2 and vincristine 1.4 mg/m 2 on days 1 and 21; prednisone 50 mg/ m 2 daily on days 1-21) and two DHAP courses (cisplatin 100 mg/m 2 on day 1 and cytarabine 2 g/m 2 every 12 h on day 2 plus dexamethasone 40 mg daily for 4 days) and (ii) high-dose phase, which involved the sequential administration of cyclophosphamide (CY, 7 g/m 2 administered intravenously (i.v.)); ara-C (2 g/m 2 twice daily for 6 consecutive days) and cisplatin (100 mg/m 2 ) plus etoposide (2.4 g/m 2 ) To reduce haematologic toxicity, 1-2 Â 10 6 CD34-positive cells/kg (collected after CY administration) were infused following Ara-C administration, and a second progenitor cell harvest was performed after Ara-C administration, as described previously. 11 The conditioning regimen included a combination of high-dose mitoxantrone (60 mg/m 2 on day À5) and melphalan (180 mg/m 2 on day À2) followed by autografting.
Thirty patients were treated with MACOP-B for 8 weeks, followed by intensification with a 3-day course of mitoxantrone 8 mg/m 2 plus high-dose Ara-C (2 g/m 2 every 12 h) 12 and granulocyte colony-stimulating factor to harvest PBPCs; conditioning regimen consisted of carmustine, etoposide, Ara-C and melphalan regimen followed by autografting. The policy of the centres involved in the two study protocols was to perform the autografting procedure with a minimum amount of 5 Â 10 6 CD34-positive cells/kg of recipient body weight. In both regimens, consolidation radiotherapy was delivered to bulky or sites of disease persistence, approximately 1 month after autografting.
During the autografting phase, patients were managed in laminar airflow rooms. All patients received prophylaxis with cotrimoxazole or pentamidine against Pneumocystis carinii infection. Acyclovir and fluconazole or itraconazole prophylaxis were routinely used. Red cell and platelet transfusions were given to maintain haemoglobin levels above 8 g/dl and platelet count above 10 Â 10 9 /l. Blood products were irradiated. Neutropaenic patients received broad-spectrum i.v. antibiotics for the management of febrile neutropaenia. Lenogastrim or filgrastim at 5 mg/kg/ day was administered subcutaneously from day þ 3, until the neutrophil count was at least 1000/ml for 3 consecutive days.
Harvest and evaluation of haemopoietic progenitors
PBPCs were mobilized and harvested after hd-CY or Ara-C. To predict the number and timing of leukaphereses, circulating CD34 þ cells along with cell blood counts were evaluated daily starting from day þ 9 following chemotherapy administration until completion of harvesting procedures. CD34 þ cell evaluation was carried out by flow cytometric direct immunofluorescence on whole-blood samples, according to published procedures. 13 A phycoerythrin-conjugated anti-CD34 monoclonal antibody was used (anti-HPCA-2, Becton Dickinson, Lincoln Park, NJ, USA), as described. 14 The number of circulating CD34 þ cells/ml of blood was obtained by multiplying the percentage of CD34 þ cells by the number of leucocytes in 1 ml of blood. Peripheral blood buffy-coat cells were collected when the white blood cell count was at least 1000/ml and PB CD34 þ cells 410/ml. Leukaphereses were performed using continuousflow blood cell separators (Cobe-Spectra or Fresenius), and 7-13 l of blood (median 8.9 l) were processed in each procedure. PBPC estimation in leukapheresis product was carried out before cryopreservation by evaluating CD34 þ cells, as detailed above. The number of circulating CD34 þ cells was obtained by multiplying this percentage by the total number of leucocytes in 1 ml of blood; the total number of CD34þ cells (10 6 /kg) in leukapheresis products was calculated by multiplying CD34 þ percentage by the total number of leucocytes collected and dividing by body weight.
Response criteria and statistical analysis
Clinical response was assessed by performing complete restaging procedures (whole-body computed tomography scan and trephine bone marrow biopsy) at 3-month intervals during first year after ASCT, and thereafter at 6-month intervals. All patients entered in the two prospective studies were evaluated by intentto treat analysis. Complete and partial remissions (CR and PR) and progressive disease (PD) were defined according to the criteria reported by Cheson et al. 15 All the time-dependent variables were computed from the day of study entry. OS was measured until death owing to any cause, and disease-free survival (DFS) for patients in CR was measured from the first recording of a CR to the date of disease relapse. EFS was calculated from the start to the first adverse event, that is, relapse or progression, secondary malignancy, treatment-related death or to the last follow-up alive. Treatment-related mortality (TRM) was defined as any death that was not attributable to the lymphoma. OS, DFS and EFS rates were estimated using the Kaplan-Meier method. 16 The closing date for analysis was 1st January 2005. Abbreviations: aaIPI, age-adjusted International Prognostic Index; AILD, angioimmunoblastic T-cell lymphoma; ALK, anaplastic lymphoma-kinase; HDS, high-dose sequential; LDH, lactate dehydrogenase; MAD, mitoxantrone-Ara-C-dexamethasone; pos., positive.
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In order to identify prognostic variables for survival and EFS, the following clinical parameters were evaluated in univariate analysis: histologic subtype, bone marrow involvement, disease status pre-transplant, aaIPI (0-1 vs 2-3), number of extranodal sites involved (o2 or X2) and type of chemotherapy schedule. These parameters were also evaluated in multivariate analysis using the stepwise Cox regression model.
Results
Clinical response and long-term outcome
Before the final autografting phase, 35 of 62 patients (56%) were in CR, 10 patients (16%) were in PR and 15 patients (24%) had PD. Two fatal toxicities were observed: one case of pneumonia and a cerebral stroke. Using an intent-to-treat analysis, 46 of 62 evaluable patients (74%) completed the whole programme, whereas 16 patients did not undergo the final autografting phase owing to the following reasons: patient refusal (n ¼ 2), poor stem cell mobilization (n ¼ 1) and disease progression (n ¼ 11). Of the patients not receiving ASCT, three patients were rescued with an allogeneic transplantation and became long-term survivors; the others underwent conventional salvage regimens, with a dismal outcome.
Overall, 41 of 46 patients (89%) were in CR after ASCT, with no significant differences between the two treatment protocols; five patients (11%) were in PR and died shortly after disease progression. There was one treatment-related death after autografting; one patient in CR died few months after autograft for a pulmonary aspergillosis. Then during the whole programme, three patients died for fatal toxicity, with a TRM rate of 4.8%. One more patient died of car accident 7 years after ASCT. In addition, the two high-dose regimens had no significant differences in terms of clinical features, response rates and grade 3-4 extra haematological toxicities.
Fourteen of 40 surviving patients in CR after ASCT relapsed; two relapses were successfully rescued with allogeneic transplantation, whereas the others died of disease progression. At a median follow-up of 76 months (range, 15-140 months), 30 of 62 (48%) patients are alive, with an estimated 12-year OS projections of 34% (Figure 1a ). At present, 24 of 62 patients (38%) are alive in continuous CR, with an estimated 12-year DFS and EFS projections of 55 and 30%, respectively (Figure 1b  and c) . Again, we did not find any statistically significant differences between the two study protocols concerning survival curves (see Table 2 ). Given the different histologic subtypes included in the study, survival curves were evaluated analysing the study population in two distinct cohorts: patients with ALKpositive ALCL compared to patients with non-ALK-positive PTCL. The OS was significantly better in patients with ALKpositive ALCL (62 vs 21%, P ¼ 0.005) ( Figure 2a) ; also, EFS was significantly superior in patients with ALK-positive when compared to non-ALK-positive (54 vs 18%, P ¼ 0.006) (Figure 2b) . Analysing separately the subgroup of PTCL unspecified, we found 12-year OS and EFS projections of 37 and 25%, respectively, which were not different from the whole group of non-ALK-positive patients. Finally, we evaluated survival curves according to the aaIPI and we found that patients with aaIPI intermediate-high risk had a poorer outcome as compared with low-risk disease, with a statistically significant difference in the EFS curve (Figure 2c ).
Prognostic parameters
Several parameters were evaluated for their prognostic value on OS and EFS in univariate analysis. As shown in Table 2 , two variables, other than histologic subtype, were found to confer a significant advantage on survival analysis: disease status pretransplant (CR achievement vs PR/NR) and intermediate-high aaIPI score. Analysing the subgroup of PTCL unspecified, we observed that CR achievement before autografting was strongly correlated to a superior EFS (62 vs 10%, respectively; P ¼ 0.003). This variable had an independent prognostic value also in multivariate analysis for both OS and EFS (Table 3) .
Discussion
The present study reports the long-term results of front-line ASCT in patients with advanced stage PTCL. Considering the disappointing results obtained using conventional chemotherapy, the aim of the study was to evaluate whether patients with PTCL could benefit from an intensified chemotherapy approach. Our results showed a relatively low TRM rate (4.8%), similar to what was reported in previous studies using intensive chemotherapy in the treatment of aggressive lymphomas.
10-17 TRM rates reported by other investigators in PTCL were slightly higher, because they ranged between 10 and 18%. Although such rates were referred to studies on relapsed PTCL, a major concern regarding the use of ASCT in PTCL was represented by the increased risk of severe or even fatal infectious complications, probably owing to a disease-related immunodeficiency. 18, 19 In our experience, we had no unusually high incidence of infectious complications.
Until recently, ASCT has been mainly performed as a salvage strategy for relapsed PTCL patients. 20, 21 A retrospective analysis performed by Rodriguez et al. 4 reported a 3-year probability of OS and progression-free survival (PFS) of 39 and 32%, respectively, in a small cohort of patients relapsed or refractory to conventional chemotherapy. Even better results were described by other investigators, reporting EFS and PFS rates ranging between 35 and 45%, respectively. 5, 18, 21, 22 However, the above-mentioned findings have some limitations: (i) the majority of the studies were single-centre experiences, with small cohorts of patients affected by different histological subtypes, which were analysed for outcome as a single entity; (ii) when separating and analysing each of the major subgroups defined by the REAL classification, only t(2;5) ALCL had a good prognosis, equivalent to diffuse large-B-cell lymphoma; for the other subtypes, most authors agreed on the adverse prognostic meaning of the T-cell phenotype; (iii) the experience of the ASCT programme of the University of Toronto in relapsed or refractory PTCL, which was the largest single institution study reported so far, showed a 3-year OS and EFS of 48 and 37%, respectively. Again, after excluding from the analysis the cohort of ALCL patients, the 3-year EFS curve dropped to 23% 5 and (iv) in these studies, the number of eligible patients, who could finally perform the autografting procedure, is unknown, owing to a lack of an intent-to-treat analysis.
The only published study evaluating the efficacy of ASCT as first-line therapy was performed in unspecified PTCLs; using an intent-to-treat analysis, nine of the 30 patients (30%) did not undergo the autografting phase, mainly because of disease Autologous stem cell transplantation in T-cell lymphoma P Corradini et al progression. For the patients actually transplanted, the results were quite encouraging: 76% of them remained in CR at a median follow-up of 15 months. However, the short follow-up cannot allow any definitive conclusion. 23 In our study, the intent-to-treat analysis showed that only 74% of patients underwent the final autografting phase. The most frequent cause of failure was disease progression; in fact, CR rate before transplant was only 56%. This figure is not higher than the one reported for patients receiving conventional chemotherapy. However, in our study, the 12-year DFS of patients in CR before ASCT was projected at 60% and seems superior to the 5-year survival projection of less than 20-25% of patients treated with CHOP-like regimens only. 1, 24, 25 Therefore, our findings suggested that consolidation of CR with autografting seems crucial and offers a greater chance of long-term survival. These results were also supported by the multivariate analysis, which showed that CR achievement before autograft was the only parameter significantly associated with a favourable outcome, both for OS and EFS.
We performed a separate analysis for patients with ALKpositive lymphomas showing a 12-year OS and EFS rates of 62 and 54%, significantly better than the ones obtained in non-ALK-positive patients (12-year OS and EFS of 21 and 18%, respectively). It is worth mentioning that the stratification in risk categories according to aaIPI influenced survival curves; in particular, the difference between low-risk and intermediatehigh-risk category became statistically significant in terms of EFS (P ¼ 0.02).
Our observation of a markedly different outcome between ALK-positive and non-ALK-positive lymphomas confirms the need of novel treatment strategies, in order to increase CR rates before ASCT and to lower relapse rates. A very recent pilot study showed that alemtuzumab, a humanized anti-CD52 monoclonal antibody, is active in T-cell lymphomas. 26 A promising response rate of 36% has been reported in a small group of heavily pretreated patients. However, the infectious complications and the haematologic toxicity observed were unacceptably high, leading to an early closure of the trial. Thus, the considerable risk of infectious complications has limited until now the inclusion of alemtuzumab in high-dose programmes.
Allogeneic transplantation is an effective and potentially curative treatment for some relapsed lymphomas. We recently reported the results of a pilot study employing reduced-intensity conditioning followed by allografting in PTCLs; although the number of patients was limited, the outcome was encouraging, suggesting the use of the procedure at least in particular subtypes of PTCL. 27 Based on these findings, we have recently started a prospective multicentre, phase II study to investigate the feasibility and efficacy of a novel intensified chemotherapy phase, including alemtuzumab followed by autologous or allogeneic transplantation according to the availability of a human leucocyte antigen-matched sibling donor.
